title: [Mycobacterium bovis tuberculosis in a female patient with AIDS].
abstract: M. bovis, the agent of bovine tuberculosis, was in other times, the main ethiological agent of tuberculosis (TBC) in industrialized countries. At the moment, the human cases have become not very frequent, except in those countries where the illness is even endemic. In patients with immunodeficiency syndrome, it usually presents as a systemic illness. We present the case of a woman with AIDS and disseminated TBC caused by M. bovis. The isolated micobacteria turned out to be resistant to rifampin and pyrazinamide. She was treated with isoniazid, ethambutol and ofloxacin with good clinical evolution. This case turned out to be the first isolation of M. bovis in a patient with AIDS, in Muñiz hospital.
authors.affiliation: Unidad XVI y Laboratorio Cetrángolo, Hospital de Enfermedades Infecciosas Francisco J. Muñiz, Uspallata 2272 (1282) Ciudad Autónoma de Buenos Aires, Argentina. mvalerga@fibertel.com.ar
authors.forename: M
authors.initials: M
authors.lastname: Valerga
authors.forename: C
authors.initials: C
authors.lastname: Viola
authors.forename: A
authors.initials: A
authors.lastname: Thwaites
authors.forename: O
authors.initials: O
authors.lastname: Bases
authors.forename: M
authors.initials: M
authors.lastname: Ambroggi
authors.forename: S
authors.initials: S
authors.lastname: Poggi
authors.forename: R
authors.initials: R
authors.lastname: Marino
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000382:microbiology*; D000328:Adult; D000437:Alcoholism / Q000150:complications; D000995:Antitubercular Agents / Q000627:therapeutic use; D001118:Argentina / Q000453:epidemiology; D019970:Cocaine-Related Disorders / Q000150:complications; D004198:Disease Susceptibility; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D016919:Meningitis, Cryptococcal / Q000150:complications; D009163:Mycobacterium bovis / Q000187:drug effects / Q000302:isolation & purification*; D015242:Ofloxacin / Q000627:therapeutic use; D045363:Pneumocystis carinii / Q000302:isolation & purification; D011020:Pneumonia, Pneumocystis / Q000150:complications / Q000382:microbiology; D011718:Pyrazinamide / Q000494:pharmacology; D012293:Rifampin / Q000494:pharmacology; D014391:Tuberculosis, Miliary / Q000150:complications / Q000453:epidemiology / Q000382:microbiology; D018088:Tuberculosis, Multidrug-Resistant / Q000150:complications / Q000453:epidemiology / Q000382:microbiology*; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000453:epidemiology / Q000382:microbiology*
chemical_list: D000995:Antitubercular Agents; D011718:Pyrazinamide; D004977:Ethambutol; D015242:Ofloxacin; D007538:Isoniazid; D012293:Rifampin